Utprøving av effekten og sikkerheten til kort- og langtidsstrålebehandling med/uten BMX-001
En randomisert fase 2-studie av effektiviteten og sikkerheten til kort- og langtidsstrålebehandling med og uten BMX-001 som en del av total neoadjuvant terapi hos pasienter med nylig diagnostisert lokalt avansert rektal adenokarsinom
In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal adenocarcinoma (RAC) patients.
Studieoversikt
Detaljert beskrivelse
In this trial, we will enroll patients in two cohorts:
Cohort 1: A 6 patient safety lead-in for patients receiving capecitabine prior to beginning a randomized trial for the Long Course Chemo-radiation (LCCRT) cohort. There will be trial stopping rules to review safety and PK data prior to initiating the randomized trial of patients receiving LCCRT.
Cohort 2: The Randomized Short Course Radiation (SCRT) cohort.
Cohort 1 and 2 will begin enrolling concurrently. Cohort 1 will have a safety lead-in of patients receiving LCCRT (with capecitabine). Cohort 2 will begin with the randomized study of patients receiving SCRT, while the LCCRT cohort is going through the safety lead-in portion.
There are stopping rules for the LCCRT cohort 1 pending PK analysis as well as an AE review from the treatment period plus 1 week post BMX-001 treatment for the 6 patients prior to moving on with the randomized portion of the study for the LCCRT cohort. All patients in the safety lead-in portion of the trial will receive BMX-001 (A loading dose of 28 mg/subject followed by maintenance doses of 14 mg/subject twice a week) with either SCRT or LCCRT. Patients will receive 3 cycles of FOLFOX or 2 cycles of CAPOX and then be assigned to SCRT or LCCRT prior to randomization. Patients will be randomized (stratified by gender) to BMX-001 or no BMX-001. The randomized trial in each cohort will involve SCRT or LCCRT with or without BMX-001. After conclusion of radiation, patients will then receive 6 more cycles of FOLFOX or 4 more cycles of CAPOX. Skin, GI, and GU symptoms will be measured on the day of screening, before and after RT.
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: IIT Office
- Telefonnummer: 402-559-4596
- E-post: IITOffice@unmc.edu
Studiesteder
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40536
- Rekruttering
- Markey Cancer Center
-
Ta kontakt med:
- Samantha F Stokely, BSN, RN
- Telefonnummer: 859-323-4128
- E-post: samantha.stokley1@uky.edu
-
Ta kontakt med:
- Cynthia A Leedham, Ph.D
- Telefonnummer: 859-257-4470
- E-post: cleed2@uky.edu
-
Hovedetterforsker:
- Mark E Bernard, MD
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68198
- Rekruttering
- University of Nebraska Medical Center
-
Hovedetterforsker:
- Chi Lin, MD, Ph.D
-
Ta kontakt med:
- IIT Office
- Telefonnummer: 402-559-4596
- E-post: IITOffice@unmc.edu
-
-
Texas
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- UT Health San Antonio MD Anderson Cancer Center
-
Ta kontakt med:
- Vanessa N Collazo Velez, RN, MS
- Telefonnummer: 210-450-7382
- E-post: collazovelez@uthscsa.edu
-
Ta kontakt med:
- James J Denno
- Telefonnummer: 210-450-5887
- E-post: dennoj@uthscsa.edu
-
Hovedetterforsker:
- Neil B Newman, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients with pathologically confirmed locally advanced rectal adenocarcinoma who will be receiving total neoadjuvant therapy regimen with curative intent.
- AJCC stage II to III rectal adenocarcinoma that will require total neoadjuvant therapy.
- Adult, age > or equal to 18 years (for Nebraska, age of consent is ≥19 years old)
- ECOG Performance Status 0-2
- Hemoglobin ≥ 9.0 g/dl, ANC ≥ 1,500 /dl, platelets ≥ 100,000 /dl (The use of transfusion or other intervention to achieve Hgb > 9.0 g/dl is acceptable)
- Serum SGOT and bilirubin ≤ 1.5 times upper limit of normal
- Adequate renal function defined as follows:
1)Serum creatinine < 1.5 mg/dl within 2 weeks prior to enrollment or 2)Creatinine clearance (CC) ≥ 50 ml/min within 2 weeks prior to enrollment determined by 24-hour collection or estimated by Cockcroft-Gault formula: CCr male = [(140 - age) x (wt in kg)]/[(Serum Cr mg/dl) x (72)], CCr female = 0.85 x (CrCl male) 8. Signed, written informed consent prior to completing any study specific procedures 9. Negative pregnancy test for women of child-bearing potential at the time of screening 10. Women of childbearing potential and male participants must agree to use two forms of a medically effective means of birth control throughout their participation in the treatment phase of the study and until 12 months following the last study treatment 11. Chest/Abdominal/Pelvic (CAP) CT/ pelvic MRI done within 8 weeks prior to randomization.
Exclusion Criteria:
-
Breast-feeding or pregnant
-
Active infection requiring IV antibiotics 7 days before enrollment
-
Prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ, basal cell or carcinoma of the skin, invasive cancers with a 5-year disease-free interval, resected cancer of the bladder or low-grade (Gleason 6 or less) prostate cancer
-
Prior history of rectal adenocarcinoma (RAC)
-
Prior history of pelvic radiotherapy for any other type of malignancy
-
Known hypersensitivity or contraindication to any agent in FOLFOX or CAPOX regimen.
-
Because corticosteroids are anti-inflammatory and could interrupt oxidative stress, patients will be excluded unless they are on stable or decreasing corticosteroids dose at the time of randomization.
BMX-001 Specific Exclusion Criteria (Subjects meeting any of the following criteria are ineligible for study entry)
-
Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure > 100 mmHg)
-
Active or history of postural hypotension and autonomic dysfunction within the past year
-
Known hypersensitivity to BMX-001
-
Clinically significant (i.e. active) cardiovascular disease or cerebrovascular disease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment, myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment
-
History or evidence upon physical/neurological examination of central nervous system disease (e.g. seizures) unrelated to cancer unless adequately controlled by medication or potentially interfering with protocol treatment
-
Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to start of study treatment
-
A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 milliseconds (ms) (CTCAE grade 1) using the specific/usual choice by clinical center for correction factor.
-
A history of additional risk factors for Torsades de Pointes (TdP) (e.g., congestive heart failure, hypokalemia, known family history of Long QT Syndrome).
Note: Inclusion of Women and Minorities Both men and women and members of all races and ethnic groups are eligible for this trial.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Arm A
Short Chemo-Radiation Therapy (SCRT) + BMX-001 |
Loading dose of 28 mg per subject, followed by maintenance doses of 14 mg per subject twice per week. |
|
Ingen inngripen: Arm B
Short Chemo-Radiation Therapy (SCRT) |
|
|
Eksperimentell: Arm C
Long Course Chemo-Radiation Therapy (LCCRT) + BMX-001 |
Loading dose of 28 mg per subject, followed by maintenance doses of 14 mg per subject twice per week. |
|
Ingen inngripen: Arm D
Long Course Chemo-Radiation Therapy (LCCRT) |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Efficacy of BMX-001 as measured by Grade 3 and above associated with gastrointestinal Toxicities
Tidsramme: Three weeks (During and 2 weeks after RT)
|
Grade 3 and above radiation-associated gastrointestinal, genitourinary, skin and hematologic toxicity (SCRT or LCCRT) including frequency, severity and duration of rectal bleeding, rectal pain, diarrhea, dysuria, hematuria, urinary frequency, radiation dermatitis and thrombocytopenia |
Three weeks (During and 2 weeks after RT)
|
|
Efficacy of BMX-001 as measured by Grade 3 and above associated with genitourinary Toxicities
Tidsramme: Three weeks (During and 2 weeks after RT)
|
Grade 3 and above radiation-associated gastrointestinal, genitourinary, skin and hematologic toxicity (SCRT or LCCRT) including frequency, severity and duration of rectal bleeding, rectal pain, diarrhea, dysuria, hematuria, urinary frequency, radiation dermatitis and thrombocytopenia |
Three weeks (During and 2 weeks after RT)
|
|
Efficacy of BMX-001 as measured by Grade 3 and above associated with skin Toxicities
Tidsramme: Three weeks (During and 2 weeks after RT)
|
Grade 3 and above radiation-associated gastrointestinal, genitourinary, skin and hematologic toxicity (SCRT or LCCRT) including frequency, severity and duration of rectal bleeding, rectal pain, diarrhea, dysuria, hematuria, urinary frequency, radiation dermatitis and thrombocytopenia |
Three weeks (During and 2 weeks after RT)
|
|
Efficacy of BMX-001 as measured by Grade 3 and above associated with hematologic Toxicities
Tidsramme: Three weeks (During and 2 weeks after RT)
|
Grade 3 and above radiation-associated gastrointestinal, genitourinary, skin and hematologic toxicity (SCRT or LCCRT) including frequency, severity and duration of rectal bleeding, rectal pain, diarrhea, dysuria, hematuria, urinary frequency, radiation dermatitis and thrombocytopenia |
Three weeks (During and 2 weeks after RT)
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Chi Lin, MD, PhD, University of Nebraska
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 0012-22-FB
- BMX-RAC-001 (Annen identifikator: BioMimetix JV, LLC)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .